questionsmedicales.fr
Phénomènes génétiques
Structures génétiques
Séquences d'acides nucléiques régulatrices
Séquences d'acides nucléiques régulatrices : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Séquences d'acides nucléiques régulatrices : Questions médicales les plus fréquentes",
"headline": "Séquences d'acides nucléiques régulatrices : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Séquences d'acides nucléiques régulatrices : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-21",
"dateModified": "2025-04-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Séquences d'acides nucléiques régulatrices"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Structures génétiques",
"url": "https://questionsmedicales.fr/mesh/D040342",
"about": {
"@type": "MedicalCondition",
"name": "Structures génétiques",
"code": {
"@type": "MedicalCode",
"code": "D040342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Réseaux de régulation génique",
"alternateName": "Gene Regulatory Networks",
"url": "https://questionsmedicales.fr/mesh/D053263",
"about": {
"@type": "MedicalCondition",
"name": "Réseaux de régulation génique",
"code": {
"@type": "MedicalCode",
"code": "D053263",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.080.689.360"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Séquences régulatrices de l'acide ribonucléique",
"alternateName": "Regulatory Sequences, Ribonucleic Acid",
"url": "https://questionsmedicales.fr/mesh/D038621",
"about": {
"@type": "MedicalCondition",
"name": "Séquences régulatrices de l'acide ribonucléique",
"code": {
"@type": "MedicalCode",
"code": "D038621",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.080.689.687"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Sites internes d'entrée des ribosomes",
"alternateName": "Internal Ribosome Entry Sites",
"url": "https://questionsmedicales.fr/mesh/D000067556",
"about": {
"@type": "MedicalCondition",
"name": "Sites internes d'entrée des ribosomes",
"code": {
"@type": "MedicalCode",
"code": "D000067556",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.080.689.687.093"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Riborégulateur",
"alternateName": "Riboswitch",
"url": "https://questionsmedicales.fr/mesh/D058928",
"about": {
"@type": "MedicalCondition",
"name": "Riborégulateur",
"code": {
"@type": "MedicalCode",
"code": "D058928",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.080.689.687.124"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Séquence d'encapsidation virale",
"alternateName": "Viral Packaging Sequence",
"url": "https://questionsmedicales.fr/mesh/D000086502",
"about": {
"@type": "MedicalCondition",
"name": "Séquence d'encapsidation virale",
"code": {
"@type": "MedicalCode",
"code": "D000086502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.080.689.905"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Séquences d'acides nucléiques régulatrices",
"alternateName": "Regulatory Sequences, Nucleic Acid",
"code": {
"@type": "MedicalCode",
"code": "D012045",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Chad A Mirkin",
"url": "https://questionsmedicales.fr/author/Chad%20A%20Mirkin",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Xiaolei Zuo",
"url": "https://questionsmedicales.fr/author/Xiaolei%20Zuo",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127 China."
}
},
{
"@type": "Person",
"name": "Qian Li",
"url": "https://questionsmedicales.fr/author/Qian%20Li",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, 200240 China."
}
},
{
"@type": "Person",
"name": "Chunhai Fan",
"url": "https://questionsmedicales.fr/author/Chunhai%20Fan",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127 China."
}
},
{
"@type": "Person",
"name": "Hanadi F Sleiman",
"url": "https://questionsmedicales.fr/author/Hanadi%20F%20Sleiman",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, McGill University, 801 Sherbrooke St W, Montréal, QC H3A 08B, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cone opponent functional domains in primary visual cortex combine signals for color appearance mechanisms.",
"datePublished": "2022-10-25",
"url": "https://questionsmedicales.fr/article/36284139",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-022-34020-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Form, synapses and orientation topography of a new cell type in layer 6 of the cat's primary visual cortex.",
"datePublished": "2022-09-14",
"url": "https://questionsmedicales.fr/article/36104476",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-19746-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "More than static: altered dynamic functional connectivity of primary visual cortex in the comitant exotropia patients.",
"datePublished": "2022-11-01",
"url": "https://questionsmedicales.fr/article/36367793",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/WNR.0000000000001849"
}
},
{
"@type": "ScholarlyArticle",
"name": "Activation of lesion projection zone in primary visual cortex is dependent on bilateral central vision loss in patients with end-stage glaucoma.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36044240",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/opo.13044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential Glial Chitotriosidase 1 and Chitinase 3-like Protein 1 Expression in the Human Primary Visual Cortex and Cerebellum after Global Hypoxia-Ischemia.",
"datePublished": "2022-11-01",
"url": "https://questionsmedicales.fr/article/36332693",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neuroscience.2022.10.018"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Séquences d'acides nucléiques régulatrices",
"item": "https://questionsmedicales.fr/mesh/D012045"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Séquences d'acides nucléiques régulatrices - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Séquences d'acides nucléiques régulatrices",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Séquences d'acides nucléiques régulatrices",
"description": "Comment identifier une séquence régulatrice ?\nQuels tests sont utilisés pour analyser les séquences régulatrices ?\nPeut-on détecter des mutations dans ces séquences ?\nQuels marqueurs sont associés aux séquences régulatrices ?\nComment évaluer l'activité d'une séquence régulatrice ?",
"url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Primary+Visual+Cortex&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Séquences d'acides nucléiques régulatrices",
"description": "Quels symptômes sont liés à des anomalies régulatrices ?\nLes séquences régulatrices affectent-elles le développement ?\nPeut-on observer des symptômes neurologiques ?\nLes troubles hormonaux sont-ils liés à ces séquences ?\nY a-t-il des symptômes immunologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Primary+Visual+Cortex&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Séquences d'acides nucléiques régulatrices",
"description": "Comment prévenir les maladies liées aux séquences régulatrices ?\nLes conseils génétiques sont-ils utiles ?\nPeut-on éviter les mutations par des choix de vie ?\nLes vaccinations jouent-elles un rôle ?\nY a-t-il des programmes de sensibilisation ?",
"url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Primary+Visual+Cortex&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Séquences d'acides nucléiques régulatrices",
"description": "Quels traitements ciblent les séquences régulatrices ?\nPeut-on corriger des mutations régulatrices ?\nLes traitements sont-ils personnalisés ?\nQuels sont les défis des traitements ?\nY a-t-il des essais cliniques en cours ?",
"url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Primary+Visual+Cortex&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Séquences d'acides nucléiques régulatrices",
"description": "Quelles complications peuvent survenir ?\nLes complications sont-elles héréditaires ?\nComment les complications sont-elles gérées ?\nY a-t-il des risques de récidive ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Primary+Visual+Cortex&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Séquences d'acides nucléiques régulatrices",
"description": "Quels sont les facteurs de risque génétiques ?\nL'environnement influence-t-il ces séquences ?\nLe mode de vie joue-t-il un rôle ?\nLes infections sont-elles un facteur de risque ?\nY a-t-il des facteurs de risque liés à l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D012045?mesh_terms=Primary+Visual+Cortex&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier une séquence régulatrice ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques comme la PCR et le séquençage."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour analyser les séquences régulatrices ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme l'empreinte génétique et l'analyse de l'expression génique sont utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans ces séquences ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations peuvent être détectées par séquençage ciblé ou NGS."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux séquences régulatrices ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs épigénétiques comme la méthylation de l'ADN sont souvent associés."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité d'une séquence régulatrice ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activité peut être évaluée par des essais de reporter génique."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à des anomalies régulatrices ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent entraîner des maladies génétiques, des cancers ou des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les séquences régulatrices affectent-elles le développement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles jouent un rôle crucial dans le développement embryonnaire et cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations régulatrices peuvent être liées à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les troubles hormonaux sont-ils liés à ces séquences ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des séquences régulatrices peuvent influencer la régulation hormonale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes immunologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent entraîner des dysfonctionnements du système immunitaire."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies liées aux séquences régulatrices ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par le dépistage génétique et la sensibilisation aux facteurs de risque."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils aident à évaluer le risque et à prendre des décisions éclairées."
}
},
{
"@type": "Question",
"name": "Peut-on éviter les mutations par des choix de vie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains choix de vie, comme l'alimentation et l'exercice, peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Les vaccinations jouent-elles un rôle ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui influencent l'expression génique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des programmes de sensibilisation ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des programmes éducatifs sensibilisent aux maladies génétiques et à leur prévention."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les séquences régulatrices ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblant des voies spécifiques sont en développement."
}
},
{
"@type": "Question",
"name": "Peut-on corriger des mutations régulatrices ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme CRISPR permettent de corriger certaines mutations."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la médecine personnalisée adapte les traitements selon le profil génétique."
}
},
{
"@type": "Question",
"name": "Quels sont les défis des traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les défis incluent la spécificité, l'efficacité et les effets secondaires potentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques en cours ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux essais cliniques explorent des thérapies ciblant ces séquences."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des troubles métaboliques et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles héréditaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être héréditaires, liées à des mutations dans les séquences régulatrices."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des traitements adaptés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de récidive ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles peuvent avoir un risque de récidive, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent significativement impacter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque génétiques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux de maladies génétiques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il ces séquences ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme les toxines peuvent affecter l'expression génique."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme et l'alimentation peuvent influencer le risque."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent déclencher des modifications dans les séquences régulatrices."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque liés à l'âge ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de maladies génétiques augmente avec l'âge."
}
}
]
}
]
}
Studies of color perception have led to mechanistic models of how cone-opponent signals from retinal ganglion cells are integrated to generate color appearance. But it is unknown how this hypothesized...
Here we report the morpho-functional features of a novel type of deep-layer neuron. The neuron was selected from a large pool of intracellularly labelled cells based on the large cell body, numerous s...
Previous neuroimaging studies have demonstrated that comitant exotropia (CE) patients exhibit dysfunction in various visual cortical areas. However, whether the CE patients showed abnormal dynamic fun...
To investigate activation of the lesion projection zone (LPZ) in the primary visual cortex during end-stage glaucoma using functional magnetic resonance imaging (fMRI), as well as the relationship bet...
Twelve subjects with bilateral end-stage glaucoma (group A), 12 with unilateral end-stage glaucoma (group B) and 12 healthy controls (group C) were enrolled. fMRI was performed under two testing stimu...
The beta values for ROIs 1-3 representing the LPZ were significantly different between the three groups under active viewing conditions, whereas no significant changes were detected under passive view...
Activation of the LPZ in the primary visual cortex was observed in patients with bilateral end-stage glaucoma under active viewing conditions. These changes were correlated with residual retinal funct...
Here, we studied the neuroinflammation- and ischemia-related glial markers chitotriosidase 1 (CHIT1) and chitinase-3-like protein 1 (CHI3L1, alias YKL-40) in the human striate cortex and cerebellum at...
Theta burst stimulation (TBS) is a type of rTMS protocol which has the advantage of a shorter delivery time over traditional rTMS. When applied to motor cortex, intermittent TBS (iTBS) has been shown ...
Using multiecho functional magnetic resonance imaging, we measured the direct and indirect effects of TBS by comparing resting state functional connectivity (FC) before and after stimulation in whole ...
We found no changes in FC for iTBS, cTBS or sham stimulation conditions from baseline to poststimulation timepoints. Additionally, cTBS and iTBS had no effect on visual cortical excitability....
Our results indicate that unlike our previous low frequency rTMS to V1 study, which resulted in widespread FC changes up to at least 1 h after stimulation, TBS to V1 does not affect FC. Contrary to th...
Divisive normalization of the neural responses by the activity of the neighboring neurons has been proposed as a fundamental operation in the nervous system based on its success in predicting neural r...
Developing optogenetic methods for research in non-human primates (NHP) is important for translational neuroscience and for delineating brain function with unprecedented specificity. Here we assess, i...
When multiple stimuli appear together in the receptive field of a visual cortical neuron, the response is typically close to the average of that neuron's response to each individual stimulus. The depa...
When multiple stimuli appear together in the receptive field of a visual cortical neuron, the response is typically close to the average of that neuron's response to each individual stimulus. The depa...